Arca
Skip to content
Tools
Tools

Histone deacetylase

Family in Homo sapiens that 10 drugs act on.

  • Drugs that act on it: 10
  • Approved: 4
  • In phases 1 to 3: 6
  • Sponsors: 8
  • Genes: 11

Who is on it, and how far along

Every drug ChEMBL records acting on HDAC1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 9
  • Protein or peptide 1

Approved4

  • Belinostat
  • Givinostat
  • Romidepsin
  • Panobinostat

Phase 33

  • Entinostat
  • Abexinostat
  • Tacedinaline

Phase 22

  • Quisinostat
  • Fimepinostat

Phase 11

  • CUDC-101

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Curis, Inc.220%
  • Xynomic Pharmaceuticals, Inc.110%

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Histone deacetylase inhibitor.
BelinostatApprovedAcrotech BiopharmaSmall moleculeInhibitor8
GivinostatApprovedItalfarmacoSmall moleculeInhibitor7
RomidepsinApprovedBristol-Myers SquibbProtein or peptideInhibitor4
PanobinostatBoxed warningApprovedSecura BioSmall moleculeInhibitor3
EntinostatPhase 3—Small moleculeInhibitor16
AbexinostatPhase 3Xynomic Pharmaceuticals, Inc.Small moleculeInhibitor6
TacedinalinePhase 3PfizerSmall moleculeInhibitor0
QuisinostatPhase 2Johnson & JohnsonSmall moleculeInhibitor2
FimepinostatPhase 2Curis, Inc.Small moleculeInhibitor1
CUDC-101Phase 1Curis, Inc.Small moleculeInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 38 in all, from ClinicalTrials.gov.
Entinostat + R-CHOP in Newly Diagnosed MYC/BCL2 Double-Expressor DLBCL: Phase II TrialEntinostatPhase 2Not yet recruitingShu ZhaoNov 16, 2026
Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene AbnormalitiesEntinostatPhase 1RecruitingBeijing Tongren HospitalOct 22, 2026
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureEntinostatPhase 1 / Phase 2RecruitingTianjin Medical University Cancer Institute and HospitalJul 16, 2026
Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaBelinostatPhase 1RecruitingCity of Hope Medical CenterJul 9, 2026
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast CancerEntinostatPhase 2RecruitingHebei Medical University Fourth HospitalMar 25, 2026
A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast CancerEntinostatPhase 2Not yet recruitingTianjin Medical University Cancer Institute and HospitalMar 2, 2026
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyEntinostatPhase 2RecruitingZhejiang Cancer HospitalJan 9, 2026
Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder CancerEntinostatPhase 1 / Phase 2Not yet recruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolDec 3, 2025
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast CancerEntinostatPhase 2Not yet recruitingSun Yat-sen UniversityNov 19, 2025
A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular DystrophyGivinostat—RecruitingITF Therapeutics LLCAug 17, 2025
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology AgentsRomidepsinPhase 1RecruitingH. Lee Moffitt Cancer Center and Research InstituteMay 9, 2025
Adjuvant Quisinostat in High-Risk Uveal MelanomaQuisinostatPhase 2RecruitingUniversity of MiamiApr 17, 2025
DMD Voice: Qualitative Interviews With Patients and CaregiversGivinostat—RecruitingRed Nucleus Enterprise Solutions, LLCApr 13, 2025
Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype GlioblastomasQuisinostatEarly phase 1Active, not recruitingNader SanaiFeb 13, 2025
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years OldGivinostatPhase 2RecruitingItalfarmacoJan 10, 2025
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaBelinostatPhase 3RecruitingCorvus Pharmaceuticals, Inc.Aug 19, 2024
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityBelinostatPhase 2RecruitingNational Cancer Institute (NCI)May 9, 2024
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraGivinostatPhase 3RecruitingItalfarmacoOct 23, 2023
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCLBelinostatPhase 3Active, not recruitingAcrotech Biopharma Inc.Oct 10, 2023
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseFimepinostatPhase 2RecruitingUniversity of California, Los AngelesAug 2, 2023
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular DystrophyGivinostatPhase 3RecruitingItalfarmacoJul 6, 2023
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerPanobinostatPhase 2RecruitingOslo University HospitalFeb 13, 2023
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent GliomaAbexinostatPhase 1RecruitingUniversity of NebraskaJan 26, 2023
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentBelinostatPhase 1Active, not recruitingNational Cancer Institute (NCI)Nov 25, 2022
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal MelanomaBelinostatPhase 2Active, not recruitingH. Lee Moffitt Cancer Center and Research InstituteDec 27, 2021
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCLBelinostat, RomidepsinPhase 2RecruitingUniversity of VirginiaFeb 10, 2021
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaBelinostatPhase 2Active, not recruitingNational Cancer Institute (NCI)Apr 10, 2020
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese PatientsAbexinostatPhase 1 / Phase 2Active, not recruitingXynomic Pharmaceuticals, Inc.Jul 18, 2019
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)AbexinostatPhase 2RecruitingXynomic Pharmaceuticals, Inc.May 3, 2019
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaAbexinostatPhase 2Active, not recruitingXynomic Pharmaceuticals, Inc.May 2, 2019
Study of Abexinostat in Patients With Relapsed or Refractory Follicular LymphomaAbexinostatPhase 2Active, not recruitingXynomic Pharmaceuticals, Inc.Jul 26, 2018
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)AbexinostatPhase 3RecruitingXynomic Pharmaceuticals, Inc.Jul 19, 2018
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability StudyGivinostatPhase 2 / Phase 3RecruitingItalfarmacoDec 14, 2017
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaRomidepsinPhase 1 / Phase 2RecruitingUniversity of VirginiaMay 19, 2017
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)RomidepsinPhase 1 / Phase 2Active, not recruitingPriyanka SharmaMar 19, 2015
CINC424A2X01B Rollover ProtocolPanobinostatPhase 4Active, not recruitingNovartis PharmaceuticalsMar 12, 2015
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsGivinostatPhase 2Active, not recruitingItalfarmacoJan 7, 2013
Study of Panobinostat (LBH589) in Patients With Sickle Cell DiseasePanobinostatPhase 1RecruitingAbdullah KutlarNov 22, 2010

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2093865, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.